Tarsus Pharmaceuticals, Inc. (TARS) — 8-K Filings

8-K Filings (13)

• Tarsus Pharma Files 8-K on Shareholder Vote Matters — Jun 18, 2025 Risk: medium
  Tarsus Pharmaceuticals, Inc. filed an 8-K on June 18, 2025, reporting on matters submitted to a vote of security holders as of June 12, 2025. The filing indicat
• DuPont Acquires Tarsus Pharmaceuticals for $1.1 Billion — Mar 18, 2025 Risk: medium
  Tarsus Pharmaceuticals, Inc. announced on March 14, 2025, that it has entered into a definitive agreement to be acquired by E.I. du Pont de Nemours and Company.
• Tarsus Pharmaceuticals Enters Material Definitive Agreement — Mar 13, 2025 Risk: medium
  Tarsus Pharmaceuticals, Inc. announced on March 12, 2025, that it has entered into a material definitive agreement. The company also reported other events and f
• Tarsus Pharmaceuticals Relocates Principal Offices — Jan 17, 2025 Risk: low
  Tarsus Pharmaceuticals, Inc. announced on January 15, 2025, a change in its principal executive offices to 15440 Laguna Canyon Road, Suite 160, Irvine, CA 92618
• Tarsus Pharmaceuticals Files Current Report — Jan 13, 2025 Risk: low
  Tarsus Pharmaceuticals, Inc. filed an 8-K on January 13, 2025, to report current information. The filing indicates the company's principal executive offices are
• Tarsus Pharma Secures $75M Loan Facility — Dec 19, 2024 Risk: medium
  On December 16, 2024, Tarsus Pharmaceuticals, Inc. entered into a Material Definitive Agreement, specifically a Loan and Security Agreement with Hercules Capita
• Tarsus Pharma Changes Exec Offices, Reports Officer/Director Updates — Nov 5, 2024 Risk: medium
  Tarsus Pharmaceuticals, Inc. announced on November 1, 2024, a change in its principal executive offices to 15440 Laguna Canyon Road, Suite 160, Irvine, CA 92618
• Tarsus Pharmaceuticals Reports on Shareholder Vote Matters — Jun 18, 2024 Risk: low
  Tarsus Pharmaceuticals, Inc. filed an 8-K on June 18, 2024, reporting on matters submitted to a vote of security holders on June 13, 2024. The filing details th
• DuPont to Acquire Tarsus Pharmaceuticals for $1.1B — Apr 23, 2024 Risk: medium
  Tarsus Pharmaceuticals, Inc. announced on April 19, 2024, that it has entered into a definitive agreement to be acquired by E.I. du Pont de Nemours and Company.
• DuPont to Acquire Tarsus Pharmaceuticals for $1.1 Billion — Mar 5, 2024 Risk: medium
  Tarsus Pharmaceuticals, Inc. announced on March 5, 2024, that it has entered into a definitive agreement to be acquired by E.I. du Pont de Nemours and Company.
• Tarsus Pharmaceuticals Files 8-K: Material Definitive Agreement — Mar 1, 2024 Risk: medium
  On February 29, 2024, Tarsus Pharmaceuticals, Inc. entered into a Material Definitive Agreement. The company, incorporated in Delaware with its principal execut
• Tarsus Pharma Reports Officer Changes & Comp Arrangements — Jan 18, 2024
  Tarsus Pharmaceuticals, Inc. filed an 8-K on January 18, 2024, reporting an event that occurred on January 11, 2024, related to the departure or appointment of
• Tarsus Pharma Files 8-K for Regulation FD Disclosure — Jan 8, 2024
  Tarsus Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, primarily to disclose information under Regulation FD and to file financial statements and exhibit

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX